This is a working overview of GRF(1-29), written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-05-13 and is reviewed periodically as new material appears.
Peptide degradation proceeds mainly through hydrolysis, oxidation of methionine, and deamidation of asparagine or glutamine residues. The maleimide group on the albumin-binding variant can also react with thiols or hydrolyze in aqueous media. Because these pathways accelerate with temperature and pH extremes, handling conditions strongly influence measured stability. Stability data in the public literature are limited and often generated under differing conditions, so general statements about shelf life should be read as approximate.
Research material is normally supplied as a freeze-dried powder in sealed vials. In that state the peptide is comparatively robust, but prolonged exposure to warmth, moisture, or light accelerates degradation. Storage at minus twenty degrees Celsius or lower, with desiccant and protection from light, is the commonly described practice. Vials should be allowed to reach room temperature before opening to limit condensation on the powder. Moisture uptake during handling is a recognized source of variability in later measurements.
Reconstitution is typically performed with sterile water or bacteriostatic water, added slowly against the vial wall. The resulting solution should be clear and colorless; cloudiness or visible particles suggest a problem with the material or the diluent. Once in solution, the peptide is less stable than the dry powder. Refrigerated storage at two to eight degrees Celsius is common for short-term holding, while freezing aliquots is described for longer periods.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white lyophilized powder | Visual descriptor; not a measure of purity |
| Solubility class | Freely soluble in water | Aqueous dissolution may require gentle mixing |
| Typical storage (powder) | −20 °C or below, desiccated | Protect from light and ambient moisture |
| Typical storage (solution) | 2–8 °C, short term | Freeze aliquots where longer holding is needed |
| Purity assessment | Reversed-phase HPLC, area percent | Values depend on column, gradient, and detection wavelength |
The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.
Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.
CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.
Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
Enzymatic protection is a separate mechanism from plasma protein binding. The four substitutions in the backbone reduce recognition by dipeptidyl peptidase IV, which normally cleaves the natural hormone within minutes. Without the reactive group, this resistance still yields only a short window of activity, generally reported in the range of tens of minutes. With it, reported half-lives in early human work extended to several days. The size of that gap is the main practical distinction between the two materials.
The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.
Naming in this area is inconsistent, and readers should treat product labels with care. In much of the literature and in vendor catalogs, the unqualified term refers to the albumin-binding version, while the version lacking the DAC group appears as modified GRF(1-29), mod GRF(1-29), or the same name with a without-DAC qualifier. Because one abbreviation has been applied to both materials, the only reliable way to identify a sample is to check the stated sequence and the presence of the linker.
=== Operation Trizor and Condor === In a joint operation funded by the United States helicopters were used to spray marijuana plants with an herbicide called paraquat. The operations eliminated 22,000 acres of poppies and 9,500 acres of marijuana fields. Of over 2,000 samples sent to the PharmaChem Foundation 22% of them were found to have been contaminated with paraquat. Laboratories in the U.S. at the time of operations' publication were overwhelmed with requests to test marijuana. The effects were estimated to potentially effect 13 million people. Due to its link to Parkinson's, pulmonary fibrosis and other diseases, the European Union banned the herbicide in 2007, followed by China in 2016.
=== Anti-mitotic agent === Moroidin has shown to have anti-mitotic properties, chiefly by inhibiting the polymerization of tubulin. Tubulin protein polymers are the major component of microtubules. During mitosis, microtubules form the organizing structure called the mitotic apparatus, which captures, aligns, and separates chromosomes. The proper alignment and separation of chromosomes is critical to ensure that cells divide their genetic material equally between daughter cells. Failure to attach chromosomes to the mitotic apparatus activates the mitotic checkpoint, preventing cells from entering anaphase to proceed with cell division. Agents that disrupt microtubules therefore inhibit mitosis through activation of this checkpoint. Moroidin and its related compounds, the celogentins, inhibit tubulin polymerization. Of this family, celogentin C is the most potent (IC50 0.8×10−6 M), and it is more potent than the anti-mitotic agent vinblastine (IC50 3.0×10−6). Moroidin has the same potency as vinblastine. Because of this biological activity, compounds in this family have potential as anti-cancer agents. The mechanism of tubulin disruption is not known, but the degree of biological activity has been linked to the structure of the right-hand ring containing the Trp-His linkage. Moroidin and the celogentins can be divided into three groups according to structural similarity of the right-hand ring. Celogentin C, the most potent compound, has a unique right-hand ring containing a proline residue.
=== Psychiatric disorders === Beta blockers have been researched for treatment of a variety of psychiatric disorders besides anxiety disorders. These include depression, mania, acute stress disorder, post-traumatic stress disorder (PTSD), schizophrenia, aggression, and agitation. Beta blockers have also been used for the treatment of schizoid personality disorder. However, there is limited evidence supporting the efficacy of supplemental beta blocker use in addition to antipsychotic drugs for treating schizophrenia.
Sources: en.wikipedia.org
Hedonism about well-being, also called prudential hedonism, holds that pleasure and pain are the only factors of well-being. It states that how well a person's life goes depends entirely on how it feels to live it, expressed as the balance of pleasure over pain. According to this view, a person who experiences frequent joy and contentment has high well-being, whereas someone who is constantly in pain and suffering has low well-being. One view sees pleasure and pain as bodily sensations, like the pleasure of eating delicious food and the pain of injuring a leg. However, hedonists generally take a wider perspective, characterizing pleasure and pain broadly as any experience that feels good or bad. This broader understanding includes the intellectual pleasure of reading an engaging book and the sorrow of losing a loved one. According to quantitative hedonism, the value of each episode of pleasure and pain depends only on its intensity and duration. Qualitative hedonism, an alternative perspective, additionally considers non-quantitative factors, arguing that some pleasures are intrinsically superior to others because of their qualitative character, even if they have the same intensity and duration. One criticism of hedonism acknowledges that some pleasures have value but rejects that this is the case for all of them. According to this view, certain pleasures have no value and may even be bad for a person, such as sadistic pleasures from torturing animals.
== Biological function == When expressed in nitrogen-fixing organisms, azurin serves as the electron donor to nitrite reductase, an enzyme in the denitrification pathway of the nitrogen cycle. Azurins support oxidative deamination of primary amines by passing electrons from aromatic amine dehydrogenase to cytochrome oxidase, as well as from some c-type cytochromes to nitrite reductases.
Cyclosporin is synthesized by a nonribosomal peptide synthetase, cyclosporin synthetase. The enzyme contains an adenylation domain, a thiolation domain, a condensation domain, and an N-methyltransferase domain. The adenylation domain is responsible for substrate recognition and activation, whereas the thiolation domain covalently binds the adenylated amino acids to phosphopantetheine, and the condensation domain elongates the peptide chain. Cyclosporin synthetase substrates include L-valine, L-leucine, L-alanine, glycine, 2-aminobutyric acid, 4-methylthreonine, and D-alanine, which is the starting amino acid in the biosynthetic process. With the adenylation domain, cyclosporin synthetase generates the acyl-adenylated amino acids, then covalently binds the amino acid to phosphopantetheine through a thioester linkage. Some of the amino acid substrates become N-methylated by S-adenosyl methionine. The cyclization step releases cyclosporin from the enzyme. Amino acids such as D-Ala and butenyl-methyl-L-threonine (Bmt) indicate cyclosporin synthetase requires the action of other enzymes. The racemization of L-Ala to D-Ala by alanine racemase is pyridoxal phosphate-dependent. The formation of butenyl-methyl-L-threonine is performed by a Bmt polyketide synthase that uses acetate/malonate as its starting material.
Cementum is slightly softer than dentin and consists of about 45% to 50% inorganic material (hydroxyapatite) by weight and 50% to 55% organic matter and water by weight. The organic portion is composed primarily of collagen and proteoglycans. Cementum is avascular, receiving its nutrition through its own imbedded cells from the surrounding vascular periodontal ligament. The cementum is light yellow and slightly lighter in color than dentin. It has the highest fluoride content of all mineralized tissue. Cementum also is permeable to a variety of materials. It is formed continuously throughout life because a new layer of cementum is deposited to keep the attachment intact as the superficial layer of cementum ages. Cementum on the root ends surrounds the apical foramen and may extend slightly onto the inner wall of the pulp canal.
Sources: en.wikipedia.org
Molybdenum is an essential element in most organisms; a 2008 research paper speculated that a scarcity of molybdenum in the Earth's early oceans may have strongly influenced the evolution of eukaryotic life (which includes all plants and animals). At least 50 molybdenum-containing enzymes have been identified, mostly in bacteria. Those enzymes include aldehyde oxidase, sulfite oxidase and xanthine oxidase. With one exception, Mo in proteins is bound by molybdopterin to give the molybdenum cofactor. The only known exception is nitrogenase, which uses the FeMoco cofactor, which has the formula Fe7MoS9C. In terms of function, molybdoenzymes catalyze the oxidation and sometimes reduction of certain small molecules in the process of regulating nitrogen, sulfur, and carbon. In some animals, and in humans, the oxidation of xanthine to uric acid, a process of purine catabolism, is catalyzed by xanthine oxidase, a molybdenum-containing enzyme. The activity of xanthine oxidase is directly proportional to the amount of molybdenum in the body. An extremely high concentration of molybdenum reverses the trend and can inhibit purine catabolism and other processes. Molybdenum concentration also affects protein synthesis, metabolism, and growth. Mo is a component in most nitrogenases. Among molybdoenzymes, nitrogenases are unique in lacking the molybdopterin. Nitrogenases catalyze the production of ammonia from atmospheric nitrogen:
=== 29 November === Jens Stoltenberg, the Secretary-General of NATO, made a speech at the meeting of NATO foreign ministers at Bucharest, in which he expressed the alliance's commitment to support Ukraine for as long as is required, because allowing Russia to win would only embolden President Vladimir Putin. He also promised Ukraine that NATO would one day accept them as a member and that Putin cannot deny sovereign nations the right to make their own sovereign decisions that were not a threat to Russia. He also speculated that the main challenges to Putin were democracy and freedom.
Cancer is a change in the cellular processes that cause a tumour to grow out of control. Cancerous cells sometimes have mutations in oncogenes, such as KRAS and CTNNB1 (β-catenin). Analysing the molecular signature of cancerous cells—the DNA and its levels of expression via messenger RNA—enables physicians to characterise the cancer and to choose the best therapy for their patients. As of 2010, assays that incorporate an array of antibodies against specific protein marker molecules are an emerging technology; there are hopes for these multiplex assays that could measure many markers at once. Other potential future biomarkers include micro RNA molecules, which cancerous cells express more of than healthy ones. Cancer is a disease with excessive molecular causes and constant evolution. There's also heterogeneity of disease even in an individual. Molecular studies of cancer have proved the significance of driver mutations in the growth and metastasis of tumors. Many technologies for detection of sequence variations have been developed for cancer research. These technologies generally can be grouped into three approaches: polymerase chain reaction (PCR), hybridization, and next-generation sequencing (NGS). Currently, a lot of PCR and hybridization assays have been approved by FDA as in vitro diagnostics. NGS assays, however, are still at an early stage in clinical diagnostics. To do the molecular diagnostic test for cancer, one of the significant issue is the DNA sequence variation detection.
=== Ion guide === Quadrupole, hexapole and other multipole ion guides can be used to transfer ions between different parts of an instrument with high efficiency. In PTR-MS they are particularly suitable for being installed in the differentially pumped interface between the reaction region and the mass spectrometer. In 2014 Sulzer et al. published an article about a PTR-MS instrument which utilizes a quadrupole ion guide between the drift tube and the TOF mass spectrometer. They reported an increase in sensitivity by a factor of 25 compared to a similar instrument without an ion guide. Quadrupole ion guides are known to have high focusing power, but also rather narrow m/z transmission bands. Hexapole ion guides on the other hand have focusing capabilities over a broader m/z band. Additionally, less energy is put into the transmitted ions, i.e. fragmentation and other adverse effects are less likely to occur. Consequently, some latest high-end PTR-MS instruments are equipped with hexapole ion guides for considerably improved performance or even with a sequential arrangement of an ion funnel followed by a hexapole ion guide for even higher sensitivity and lower detection limit.
==== Exact analytical solutions to the SIR model ==== In 2014, Harko and coauthors derived an exact so-called analytical solution (involving an integral that can only be calculated numerically) to the SIR model. In the case without vital dynamics setup, for
Sources: en.wikipedia.org
Cool, dark, and dry conditions are standard, with storage at minus twenty degrees Celsius or below. Desiccant and sealed vials limit moisture uptake. Repeated warming and cooling of the container is generally avoided.
There is no single agreed limit, and laboratory practice varies widely. Refrigeration slows degradation, and freezing aliquots is often described for longer holding. Any visible cloudiness or precipitate indicates the solution should be discarded.
Mass spectrometry provides the most direct confirmation through molecular mass. Reversed-phase chromatography supports purity assessment, and peptide mapping or amino acid analysis can corroborate sequence. No single method establishes both purity and identity on its own.
The two share the same 29-amino-acid backbone. CJC-1295 carries an additional albumin-binding moiety that markedly extends its residence time in circulation, while the form without that moiety clears faster. Literature sometimes applies the name loosely to either variant.